11 September 2024

College issues guidance on managing possible mpox cases in primary eye care settings

The guidance on mpox (previously known as monkeypox) is to ensure clinicians are aware of signs, symptoms and how to manage possible cases.

The World Health Organization (WHO) recently declared the increase of Clade I Mpox virus (MPXV) cases in Central and East Africa as a public health emergency of international concern. Clade I is linked to higher rates of severe illness and mortality compared to the less dangerous Clade II. 

What is mpox?

Mpox (MPXV) is a virus related to smallpox, transmitted through direct contact with infected skin, mucous membranes, or contaminated surfaces. It can also spread via respiratory droplets. 

The incubation period ranges from 5 to 21 days, with most people recovering within weeks. While there's no specific cure, supportive treatment and antiviral drugs can help those with severe illness or at high risk. 

There are two clades of MPXV: 

  • Clade I is classified as a high consequence infectious disease (HCID)
  • Clade II is generally milder and not considered an HCID. 

Symptoms include fever, headache, muscle aches, and a rash that progresses through several stages.

While Clade I cases remain isolated in Europe and none have been reported in the UK, healthcare providers are advised to be prepared for any suspected cases. As a result, the College has issued guidance for those providing eye care in primary care settings.

Related further reading

For the very last issue of Optometry in Practice, Professor Jonathan Jackson MCOptom reflects on the past two decades of the journal and its contribution to our learning.

This paper describes how viruses infect, reproduce and damage cells. Knowing this process is critical for understanding how to treat ocular viral infections.